«1234»Seite
4 articles with references, page 2 of 4

Review article

Current Standards in the Treatment of Chronic Hepatitis C

Dtsch Arztebl Int 2012; 109(19): 352-8; DOI: 10.3238/arztebl.2012.0352

Hofmann, W P; Sarrazin, C; Zeuzem, S

1. Sarrazin C, Berg T, Ross RS, et al.: [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol 2010; 48: 289–351. CrossRef MEDLINE
2.Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: 35–46. CrossRef MEDLINE
3.Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: 35–50. CrossRef MEDLINE
4.Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65. CrossRef MEDLINE
5.Zeuzem S, Hultcrantz R, Bourliere M, et al.: Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993–9. CrossRef MEDLINE
6.Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82. CrossRef MEDLINE
7. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245–64. CrossRef MEDLINE
8.Simmonds P, Bukh J, Combet C, et al.: Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962–73. CrossRef MEDLINE
9.Kau A, Vermehren J, Sarrazin C: Treatment predictors of a sustained virologic response in hepatitis B and C. Journal of Hepatology 2008; 49: 634–51. CrossRef MEDLINE
10.Clark PJ, Thompson AJ, McHutchison JG: IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection: The Future of Personalized HCV Therapies. Am J Gastroenterol 2011; 106: 38–45. CrossRef MEDLINE
11.Veldt BJ, Heathcote EJ, Wedemeyer H, et al:. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677–84. MEDLINE
12.Poynard T, Colombo M, Bruix J, et al.: Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618–28.e1612. MEDLINE
13.Jensen DM, Marcellin P, Freilich B, et al.: Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528–40. MEDLINE
14.Soriano V, Vispo E, Poveda E, et al.: Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011; 66: 1673–86. CrossRef MEDLINE
15.Sarrazin C, Berg T, Cornberg M, et al.: [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol 2012; 50: 57–72. CrossRef MEDLINE
16.Hofmann WP, Zeuzem S: A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8: 257–64. MEDLINE
17.Poordad F, McCone J, Bacon B, et al.: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195–206. CrossRef MEDLINE
18.Kwo PY, Lawitz EJ, McCone J, et al.: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705–16. CrossRef MEDLINE
19.Jacobson IM, McHutchison JG, Dusheiko G, et al.: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405–16. CrossRef MEDLINE
20.Sherman KE, Flamm SL, Afdhal NH, et al.: Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014–24. CrossRef MEDLINE
21.Bacon B, Gordon SC, Lawitz E, et al.: HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207–17. CrossRef MEDLINE PubMed Central
22.Zeuzem S, Andreone P, Pol S, et al.: Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417–28. CrossRef MEDLINE
23.Sarrazin C, Zeuzem S. Resistance to Direct Antiviral Agents in Patients with Hepatitis C Virus Infection. Gastroenterology 2010; 138: 447–62. CrossRef MEDLINE
24.Boceprevir-Nutzenbewertung des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) gemäß § 35a SGB V (Dossierbewertung). Stellungnahme des Vorstands der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2012; 50: 20–1.
25.Telaprevir-Nutzenbewertung des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) gemäß § 35a SGB V (Dossierbewertung). Stellungnahme des Vorstands der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2012; 50: 271–2.